Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › GUFICBIO

GUFICBIO

Gufic Biosciences Limited
Micro-capPharma ↗

What the six lenses say about GUFICBIO — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹448.0
2026-09-08
VWAP · 1Y anchor
₹372
+20.4% from VWAP
P/E · TTM
70.0×
TTM EPS ₹6.4
52-week range
100%
position low→high
RSI(14)
68
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How GUFICBIO’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
8.0
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+20.4%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+25.0%
Price vs 50-EMA+11.3%
RSI(14)68
RS vs Nifty 500 · 3M+14.5%
RS vs sector · 3M+8.5%
52-week range100%
Volume vs 30d avg0.51×
Volume vs 60d avg0.26×
ATR(14) · volatility20.0
Bollinger width · vol contraction0.109
FundamentalD434›

The actual numbers

Return on equity (ROE)9.6%
Operating margin13.0%
Net margin6.8%
Revenue growth · YoY+15.2%
EPS growth · YoY-7.9%
Debt / equity0.61×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)70.0×
TTM EPS₹6.4
52-week range100%
CatalystD328›

The actual numbers

Earnings & momentum21
Capital actions30
Governance48

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding72.5%
Delivery · 30d avg51.6%
Up/down-day asymmetry0.7pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D6 ) ÷ 2 = 8.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 8.0/10
Conviction score95/100›
TechnicalD10›
FundamentalD4›
ValuationD1›
CatalystD3›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.2pp
+8.9pp
+14.3pp
+16.1pp
+63.2pp
+29.4pp
Nifty 500
Broad-market baseline
+1.1pp
+8.9pp
+13.2pp
+14.5pp
+57.5pp
+24.2pp
Sector
Own-sector index
—
—
+10.4pp
+8.5pp
+44.4pp
+3.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

GUFICBIO daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
448.00+3.10

Relative strength

RS vs baseline · rebased to 100

GUFICBIO ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
115.99+1.29

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)203204208205224237231252
↳ change QoQ—+0.7%+1.8%-1.3%+9.3%+5.8%-2.5%+9.1%
EBITDA (₹cr)3739362633383347
EBITDA margin18.3%19.0%17.2%12.7%14.7%16.0%14.3%18.6%
PAT (₹cr)212219813171222
↳ change QoQ—+4.4%-11.3%-58.6%+62.5%+30.8%-29.4%+83.3%
Net margin10.3%10.7%9.3%3.9%5.8%7.2%5.2%8.7%
EPS (₹)2.082.171.930.771.301.681.242.18
D/E————————
YoY growth · Mar '26Revenue +22.9% YoYPAT +175.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Sep '26
    MEDIUMcapital
    Credit Rating
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 2 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    HIGHcapital
    Acquisition
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 14 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 Jun '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    HIGHgovernance
    Change in Auditors
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    HIGHcapital
    Acquisition
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds GUFICBIO

Mutual funds holding GUFICBIO (2)

FundWeightAUM ₹crGrade
Bank of India Small Cap Reg Gr0.79%2,819
Bank of India Manfactrg & Infra Gr0.87%893

ETFs holding GUFICBIO (0)

No tracked ETF holds GUFICBIO ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma